DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Mallinckrodt

Mallinckrodt

  • Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials

    Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials

  • Endo Pharmaceuticals Inc. V. Actavis

    Endo Pharmaceuticals Inc. V. Actavis

  • Amgen Inc. V. Sanofi, No

    Amgen Inc. V. Sanofi, No

  • Driving Awareness and Action Around the Country's

    Driving Awareness and Action Around the Country's

  • Compliance Officers.Xlsx

    Compliance Officers.Xlsx

  • Rxoutlook® 4Th Quarter 2020

    Rxoutlook® 4Th Quarter 2020

  • PROXY MEMORANDUM To: Shareholders of Pfizer Re: Shareholder Resolution on Political Lobbying Disclosure Date: March 18, 2020 Co

    PROXY MEMORANDUM To: Shareholders of Pfizer Re: Shareholder Resolution on Political Lobbying Disclosure Date: March 18, 2020 Co

  • In the United States District Court for the District of Delaware

    In the United States District Court for the District of Delaware

  • Determination of Serum Fentanyl Levels After Using Reference and Generic Transdermal Fentanyl Patches with and Without Standardi

    Determination of Serum Fentanyl Levels After Using Reference and Generic Transdermal Fentanyl Patches with and Without Standardi

  • Statement of Chairman Joseph J. Simons, Commissioner Noah Joshua Phillips, and Commissioner Christine S

    Statement of Chairman Joseph J. Simons, Commissioner Noah Joshua Phillips, and Commissioner Christine S

  • 20200921162657229 Idenix V. Gilead

    20200921162657229 Idenix V. Gilead

  • COVID-19 Vaccination-Related Lymphadenopathy: What to Be Aware Of

    COVID-19 Vaccination-Related Lymphadenopathy: What to Be Aware Of

  • Late Additions Will Be Reported Within Daily Addenda During Conference. ATS Requires Disclosure of Commercial Interests Within Past 3 Years Or Expected by End of 2019

    Late Additions Will Be Reported Within Daily Addenda During Conference. ATS Requires Disclosure of Commercial Interests Within Past 3 Years Or Expected by End of 2019

  • Case 1:19-Cv-12117-PBS Document 1 Filed 10/11/19 Page 1 of 198

    Case 1:19-Cv-12117-PBS Document 1 Filed 10/11/19 Page 1 of 198

  • Compliance Officers

    Compliance Officers

  • 14-1381 0.Pdf

    14-1381 0.Pdf

  • UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION IN

    UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION IN

  • First Name Last Name Disclosure Enass Abdel-Hameed Nothing To

    First Name Last Name Disclosure Enass Abdel-Hameed Nothing To

Top View
  • Current Sustaining Member Companies
  • Biopharma Boom Fosters Deal Spree
  • FORM 10-Q Johnson & Johnson
  • Edward Mallinckrodt Jr. Papers (S0452)
  • Covidien Aims for Abbvie Mk II with Mallinckrodt Spinout
  • Washington, D.C. Area
  • Mallinckrodt Public Limited Company (Name of Registrant As Specified in Its Charter)
  • National Prescription ) Case No. 1:17 Md 2804 Op
  • Bausch Health 2019 Annual Report
  • Declaration of Disclosure Faculty Disclosures
  • Mallinckrodt Plc
  • IN the UNITED STATES DISTRICT COURT for the DISTRICT of DELAWARE MALLINCKRODT IP, Plaintiff, V. MYLAN LABORATORIES LTD. and AGIL
  • January 22, 2018
  • 4Q2015 Active Labeler Labeler Company 00002 ELI LILLY and COMPANY 00003 E.R
  • Faculty Disclosures
  • 20200915 MED-Project Participant List.Xlsx
  • United States District Court for the Western District of Kentucky
  • 685.1 Cephalon, Inc.; Teva Pharmaceutical Industries Ltd.; Teva Pharmaceuticals USA, Inc.; Endo


© 2024 Docslib.org    Feedback